Dissecting the Influence of Two Structural Substituents on the Differential Neurotoxic Effects of Acute Methamphetamine and Mephedrone Treatment on Dopamine Nerve Endings with the Use of 4-Methylmethamphetamine and Methcathinone

John H. Anneken, Mariana Angoa-Perez, Girish C. Sati, David Crich, and Donald M. Kuhn

Research & Development Service, John D. Dingell VA Medical Center, Detroit, MI (J.A., M.A., D.K.); Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI (J.A., M.A., D.K.); Department of Chemistry, Wayne State University, Detroit, MI (G.S. and D.C.).
Running Title: Neurotoxicity of 4-Methylmethamphetamine and Methcathinone

Corresponding Author: Dr. Donald M. Kuhn, John D. Dingell VA Medical Center, R&D Service (11R), John D. Dingell VA Medical Center, 4646 John R, Detroit, MI, 48201, USA, Tel: +1 313 576 4457, Fax: +1 313 576 1112. Email: donald.kuhn@wayne.edu

Text Pages: 30
Figures: 4
References: 54
Abstract: 244 words
Introduction: 737 words
Discussion: 1499 words

**ABBREVIATIONS:** 4MM, 4-methylmethamphetamine; 5-HT, serotonin; ANOVA, analysis of variance; DA, dopamine; DAT, dopamine transporter; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GFAP, glial fibrillary acid protein; HPLC, high performance liquid chromatography; MeCa, methcathinone; MEPH, mephedrone; METH, methamphetamine; TH, tyrosine hydroxylase; VMAT₂, vesicular monoamine transporter-2

Recommended Review Section: Neuropharmacology
Abstract

Mephedrone (MEPH) is a β-ketoamphetamine stimulant drug of abuse that is often a constituent of illicit bath salts formulations. While MEPH bears remarkable similarities to methamphetamine (METH) in terms of chemical structure, as well as its neurochemical and behavioral effects, it has been shown to have a reduced neurotoxic profile compared to METH. The addition of a β-keto moiety and a 4-methyl ring substituent to METH yields MEPH, and a loss of direct neurotoxic potential. In the present study, 2 analogs of METH, methcathinone (MeCa) and 4-methylmethamphetamine (4MM), were assessed for their effects on mouse dopamine (DA) nerve endings to determine the relative contribution of each individual moiety to the loss of direct neurotoxicity in MEPH. Both MeCa and 4MM caused significant alterations in core body temperature as well as locomotor activity and stereotypy, but 4MM was found to elicit minimal dopaminergic toxicity only at the highest dose. By contrast, MeCa caused significant reductions in all markers of DA nerve ending damage over a range of doses. These results lead to the conclusion that ring substitution at the 4-position profoundly reduces the neurotoxicity of METH, whereas the β-keto group has much less influence on this property. While the mechanism(s) by which the 4-methyl substituent reduces METH-induced neurotoxicity remains unclear, it is speculated that this effect is mediated by a loss of DA-releasing action in MEPH and 4MM at the synaptic vesicle monoamine transporter, an effect that is thought to be critical for METH-induced neurotoxicity.
Introduction

β-ketoamphetamines (bath salts) are an increasingly popular class of abused stimulants that represent an emerging public health concern. These compounds, including mephedrone (MEPH), methylone, and MDPV, are the β-keto analogs to the classic amphetamines drugs. Although now illegal, bath salts are still being frequently abused, primarily due to their subjective effects which include euphoria and increased sex drive (Johnson and Johnson, 2014). These effects are thought to be elicited by the release of dopamine (DA), serotonin (5-HT), and norepinephrine through their respective reuptake transporters, as the β-ketoamphetamines are known to have potent reuptake inhibition and releasing effects on these targets (Baumann et al., 2012, Cameron et al., 2013, Eshleman et al., 2013, Lopez-Arnau et al., 2012, Simmler et al., 2013). The synthetic cathinones found in bath salts are less apt to produce lasting neurotoxicity compared to 3,4-methylenedioxymethamphetmine (MDMA) and methamphetamine (METH) (Angoa-Perez et al., 2012, Anneken et al., 2015, Baumann et al., 2012, den Hollander et al., 2013, Motbey et al., 2013). This is despite a striking similarity in acute neurochemical and behavioral effects, including the aforementioned monoamine release, thermoregulation (Aarde et al., 2015, Baumann et al., 2012, Fantegrossi et al., 2013, Kiyatkin et al., 2015, Lopez-Arnau et al., 2014, Martinez-Clemente et al., 2014, Shortall et al., 2015), hyperlocomotion (Aarde et al., 2015, Aarde et al., 2013, Baumann et al., 2012, Fantegrossi et al., 2013, Gatch et al., 2013, Lopez-Arnau et al., 2012, Marusich et al., 2012, Motbey et al., 2012, Wright et al., 2012), and measures of abuse potential (Aarde et al., 2015, Aarde et al., 2013, Hadlock et al., 2011, Karlsson et al., 2014, Lisek et al., 2012, Motbey et al., 2013, Watterson et al., 2012).

These classic abused stimulants, 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine (METH), share structures highly similar to the bath salts but have long been
known to elicit lasting neurotoxicity. In mouse studies, this toxicity primarily impacts
dopaminergic axons in the forebrain (Moratalla et al., 2015). METH elicits a pronounced
depletion in both tissue DA content and in protein markers of dopaminergic terminals, including
the dopamine transporter (DAT) and the synthetic enzyme tyrosine hydroxylase (TH)
(McConnell et al., 2015). This toxicity is widely thought to be mediated by oxidative stress as
evidenced by increases in reactive oxygen and nitrogen species, resulting in damage to cellular
components (Yamamoto and Raudensky, 2008). However, the key triggering mechanism for this
cascade of damage has remained elusive. It has been proposed that these effects could be
mediated by excessive DA release, mitochondrial dysfunction, or inflammation, among other
interrelated processes (Halpin et al., 2014).

The divergence in persistent monoaminergic depletion between bath salts and
amphetamines provides a unique opportunity to identify more precisely the key mechanism(s)
responsible for long-term neurotoxicity. To this end, the bath salt MEPH can be particularly
useful in studying METH toxicity. Although there has been reported DA depletion when MEPH
is given at elevated ambient temperatures, as well as a potentially toxic in vitro effect (den
Hollander et al., 2014, Martinez-Clemente et al., 2014), numerous studies conducted in this
laboratory and others under ambient conditions known to produce METH toxicity have reported
no significant long-term in vivo dopaminergic neurotoxicity when MEPH is administered in a
binge regimen (Angoa-Perez et al., 2013, Angoa-Perez et al., 2012, Anneken et al., 2015,
Baumann et al., 2012, den Hollander et al., 2013, Motbey et al., 2013). As shown in Fig. 1,
MEPH differs from METH by two structural modifications: i) a β-keto substitution, and ii) the
presence of a 4-methyl group on the phenyl ring. By utilizing two compounds each carrying one
of the two modifications, 4-methylmethamphetamine (4MM) and methcathinone (MeCa), it may
be possible to identify which of these substituents is responsible for the observed lack of direct
toxicity in MEPH, and additionally to provide insight on the key mechanism that initiates the
toxic effects of METH.

To date, no study has investigated the toxic potential of 4MM. A limited number of
studies have been conducted examining MeCa which have documented dopaminergic toxicity,
although there is variation in the effect sizes reported (Gygi et al., 1997, Gygi et al., 1996,
Sparago et al., 1996). Therefore, it was the objective of this study to compare the neurotoxicity
of these two intermediates. Both compounds significantly altered body temperature and
locomotion, but only MeCa evoked significant dopaminergic toxicity. These results suggest that
ring substituents in bath salt components have more impact on lessening neurotoxic potential
than does the β-keto moiety.
Materials and Methods

Drugs and reagents

(R,S)-N-Methcathinone HCl was obtained from the NIDA Research Resources Drug Supply Program. Racemic 4MM was synthesized as described by Davis et al. (2012) from methylamine HCL and 4-methylphenylacetone purchased from Alfa Aesar (Ward Hill, MA, USA), and its structure was confirmed by NMR and MS. DA, polyclonal antibodies against glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and all buffers and HPLC reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA). Bicinchoninic acid protein assay kits were obtained from Pierce (Rockford, IL, USA). Polyclonal antibodies against rat tyrosine hydroxylase (TH) were produced as previously described (Kuhn and Billingsley, 1987). Monoclonal antibodies against rat DAT were generously provided by Dr. Roxanne A. Vaughan (University of North Dakota, Grand Forks, ND, USA). Polyclonal antibodies against glial fibrillary acidic protein (GFAP) were obtained from Thermo Scientific (Rockford, IL). IRDye secondary antibodies for Odyssey Imaging Systems were purchased from LiCor Biosciences (Lincoln, NE).

Animals

Female C57BL/6 mice (Harlan, Indianapolis, IN, USA) weighing 18-25 g at the time of experimentation were housed 5-7 per cage in large shoe-box cages in a light (12 h light/dark) and temperature controlled room. Female mice were used as they are very sensitive to neurotoxicity induced by amphetamines and to maintain consistency with our previous studies of METH and β-ketoamphetamine interactions (Angoa-Perez et al., 2013, Angoa-Perez et al., 2012, Angoa-Perez et al., 2014, Anneken et al., 2015). Mice had free access to food and water. The mice used
were randomly divided into treatment groups. The Institutional Care and Use Committee of Wayne State University approved the animal care and experimental procedures. All procedures were also in compliance with the NIH *Guide for the Care and Use of Laboratory Animals* and were conducted in compliance with ARRIVE guidelines and under IACUC-approved protocols.

**Drug treatments**

Mice were treated i.p. with 4 total injections of drug in a binge-like regimen, with 2 h intervals between each administration. Each injection contained either 4MM (2.5, 5, 10, 20, or 40 mg/kg), MeCa (10, 20, 40, or 80 mg/kg), or saline vehicle, given in 200 µL volume. The cumulative doses for 4MM over 4 injections were 10, 20, 40, 80 or 160 mg/kg, while for MeCa, they were 40, 80, 160, or 320 mg/kg. This binge treatment regimen has been established by multiple prior studies in this laboratory and others, and elicits significant neurotoxicity for amphetamine compounds. Doses of MeCa used fall within the range used in similar published studies (Gygi et al., 1997, Gygi et al., 1996, Sparago et al., 1996), while the range of 4MM doses used were chosen to compare with studies involving METH and other β-ketoamphetamines (Angoa-Perez et al., 2013, Angoa-Perez et al., 2012, Angoa-Perez et al., 2014, Anneken et al., 2015). Mice were sacrificed 48 h after the last drug treatment when amphetamine-associated neurotoxicity is known to reach maximal levels.

**Determination of striatal DA content**

Striatal tissue was dissected from the brain after treatment and stored at –80°C. Frozen tissues were weighed and sonicated in 10 volumes of 0.16 N perchloric acid at 4°C. Insoluble protein was removed by centrifugation and DA was determined by HPLC with electrochemical detection as previously described (Angoa-Perez et al., 2013, Angoa-Perez et al., 2012).
Determination of DAT, TH and GFAP protein levels by immunoblotting

The effects of drug treatments on striatal DAT and TH levels, highly specific markers for striatal DA nerve endings, were determined by immunoblotting as an index of toxicity. GFAP levels were determined as a marker of neuroinflammation, as described previously (Angoa-Perez et al., 2012). Mice were sacrificed by decapitation 48 h after treatment and striata were dissected bilaterally. Tissue was stored at -80°C. Frozen tissue was disrupted by sonication in 1% SDS at 95°C and insoluble material was removed by centrifugation. The concentration of soluble protein was determined by the bicinchoninic acid method and equal amounts of protein (70 µg/lane) were resolved by SDS-polyacrylamide gel electrophoresis and then electroblotted to nitrocellulose. Blots were blocked in Odyssey blocking buffer (PBS) for 1 h at room temperature. Primary antibodies against DAT (1:1,000), TH (1:1,000), GFAP (1:2,000) or GAPDH (1:10,000) were added to blots and allowed to incubate overnight at 4°C. Blots were washed 3x in Tris-buffered saline to remove unreacted antibodies and then incubated with IRDye secondary antibodies (1:4000) for 1 h at room temperature. Immunoreactive bands were visualized by enhanced fluorescence and the relative densities of TH-, DAT-, GFAP- and GAPDH-reactive bands were determined by imaging with an Odyssey CLx Infrared Image System (LiCor Biosciences, Lincoln, NE) and quantified using ImageJ software (NIH). TH, DAT and GFAP relative densities were normalized to the GAPDH level for each lane to control for loading error.

Body temperature

Core body temperatures were monitored in treated animals by telemetry using IPTT-300 implantable temperature transponders from Bio Medic Data Systems, Inc. (Seaford, DE, USA)
inserted subcutaneously. Temperatures were recorded non-invasively every 20 min starting 60 min before the first drug injection and continuing for 9 h thereafter using the DAS-5001 console system from Bio Medic. The averaged mean difference across all time points was calculated for each treatment compared to controls.

**Locomotor activity and stereotypy**

Mice were treated with either vehicle, MeCa (20, 40 or 80 mg/kg), or 4MM (2.5, 5, 10, 20, or 40 mg/kg) using the same binge regimen described above. Immediately following each injection, mice were placed in locomotor activity monitoring cages (Omnitech Electronics, Inc., Columbus, OH), divided into 20 cm x 20 cm quadrants with accompanying inserts. Parameters including locomotor activity as measured in horizontal beam breaks, movement time, and stereotypy, as measured by vertical beam breaks, were tracked for 60 min using Fusion photobeams and software (Omnitech Electronics, Inc.). Animals were then placed into the home cage for 60 min of food and water access. This process was repeated for each animal throughout drug administration. The data acquired over 4 h of monitoring were pooled for each animal, and averaged for each treatment group.

**Data analysis**

Group sizes, given in the figure legends, were based on prior experiments in this laboratory. Certain control groups are larger due to pooling of multiple experiments. In Figure 2, the group sizes given are for animals treated, but there is some variation in the group size analyzed for some markers due to sample loss during processing. None of the data presented reflect replicates, only discreetly-treated individuals. The effects of drug treatments on core body temperature over time were analyzed using two-way ANOVAs and post hoc comparisons were carried out using
Bonferroni’s Test. One-way ANOVAs were performed to analyze the dose effects of 4MM and MeCa on striatal levels of DA, DAT, TH and GFAP, with post hoc comparisons carried out using Bonferroni’s Test. Locomotor effects of each drug were also analyzed using one-way ANOVAs, and post hoc tests were conducted with Bonferroni’s Test. Differences were considered significant if $p < 0.05$. All statistical analyses were carried out using GraphPad Prism version 6.01 for Windows (GraphPad Software, San Diego, CA, USA, [www.graphpad.com](http://www.graphpad.com)).
Results

Toxic effects of 4MM and MeCa on markers of striatal dopaminergic nerve endings

The effects of 4MM and MeCa on DA, DAT, TH, and GFAP are shown in Fig. 2. Typical toxicity over a range of doses for METH (2.5-10 mg/kg) as well as MEPH (20-40 mg/kg) is also included from a prior publication and supplemental experiments from our laboratory for comparison (Anneken et al., 2015). There was very little toxicity elicited by 4MM, with only the highest dose evoking a significant reduction (20%) in striatal DA (Fig. 2A; F(5,53) = 3.32, p < 0.05), while all doses of MeCa except 10 mg/kg resulted in significant DA reductions (Fig. 2A; F(4,42) = 32.21, p < 0.0001). However, while 4MM at the highest dose showed only a non-significant trend of 10% reduction in DAT levels, MeCa reduced this marker significantly at the three highest doses assessed (Fig. 2B; F(4,39) = 25.72, p < 0.0001). 4MM had no significant effect on TH at any dose, but MeCa evoked a significant reduction at 20-80 mg/kg (Fig. 2C; F(4,39) = 21.90, p < 0.0001). Finally, no dose of 4MM had a significant effect on the inflammatory marker GFAP, but all doses of MeCa caused significant elevation in GFAP levels (Fig. 2D; F(4,39) = 18.44, p < 0.0001).

Effects of 4MM and MeCa on core body temperature

The body temperature effects of 4MM and MeCa were monitored for the duration of the experiments for the same cohorts of mice evaluated for dopaminergic toxicity. As shown in Fig. 3A, 4MM elicited a dose-dependent increase in body temperature over the course of binge treatment. A two-way ANOVA revealed highly significant main effects of treatment (F(5,19) = 144.0, p < 0.0001) and time (F(30,570) = 4.99, p < 0.0001), as well as a significant interaction of
the two (F(150, 570) = 1.94, p < 0.0001). The results of a post-hoc comparison over the duration of the entire experiment using Bonferroni’s test is shown in Fig. 3B, with significance indicated over the mean difference of each treatment dose compared to controls across all time points. As demonstrated, all doses elicited significant hyperthermia compared to control animals with magnitudes increasing in a dose-dependent manner.

As shown in Fig. 3C, MeCa also significantly impacted core body temperature in a dose-dependent, albeit unusual, manner. Highly significant main effects of treatment (F(3,29) = 53.86, p < 0.0001) and time (F(30, 870) = 5.63, p < 0.0001) were revealed by two-way ANOVA, as was a significant interaction between the two factors (F(90,870) = 7.17, p < 0.0001). The results of a post-hoc comparison over the duration of the entire experiment using Bonferroni’s Test is shown in Fig. 3D, with significance indicated over the mean difference of each treatment dose compared to controls across all time points. There was a significant hyperthermia elicited by 20 and 40 mg/kg, while at the 80 mg/kg dose there was a profound, persistent hypothermia following each injection of MeCa.

Effects of 4MM and MeCa on locomotor activity and stereotypy

As most stimulants are known to increase the amount of locomotor activity via increased DA release, separate cohorts of mice were administered the binge regimen of 4MM and MeCa, and were monitored for parameters of horizontal beam breaks, movement time, and stereotypy time over 4 h total, measured for 1 h at a time following each of the four injections.

As shown in Figure 4, 4MM given at 5-20 mg/kg induced a significant increase in horizontal activity, as quantified by horizontal beam breaks (Fig. 4A; F(5,28) = 6.94, p < 0.001),
while there were no significant changes in this parameter elicited by any dose of MeCa. Furthermore, all doses except the lowest of 4MM significantly increased the time spent in motion (Fig. 4B; $F_{(5,28)} = 12.48, p < 0.0001$), but only the lowest dose assessed for MeCa increased this parameter (Fig. 4B; $F_{(3,12)} = 5.05, p < 0.05$). Finally, there was a trend for increased stereotypy (i.e. rearing, grooming, etc.) as measured by time spent in vertical motion for most doses of 4MM, but this only achieved significance at 5 and 40 mg/kg (Fig. 4C; $F_{(5,28)} = 6.94, p < 0.01$). All administered doses of MeCa (Fig. 4C; $F_{(3,12)} = 7.69, p < 0.01$) caused a significant increase in stereotyped behavior, and these increases were of greater magnitude than those seen in 4MM.
Discussion

The studies presented in this report sought to dissect the individual contributions of two substituents, a 4-methyl group and a β-keto group, to observed differences in neurotoxicity between METH and its structural analog, the bath salt MEPH. The availability of structural analogs carrying the individual substituents, 4MM and MeCa, provided a means to probe the relative contributions of each group.

In Fig. 2, 4MM exhibited only a slight reduction in DA at the highest dose given (40 mg/kg), with no significant changes observed in DAT, TH, or GFAP at any dose. To our knowledge, this is the first neurotoxic investigation of this compound. Conversely, MeCa evoked a significant reduction in DA, DAT, and TH at 20-80 mg/kg, as well as a significant increase in GFAP at 10-80 mg/kg. The neurotoxicity of MeCa demonstrated here is in agreement with earlier binge studies that found depletions of dopaminergic markers at similar doses in the literature (30-120 mg/kg) (Gygi et al., 1997, Gygi et al., 1996, Sparago et al., 1996). The depletions observed exceeded the MEPH effects, which were non-significant at 20-40 mg/kg, but were not as pronounced as those evoked by METH in prior work in this lab, and required much higher doses than the 2.5-10 mg/kg binge dosing for METH needed for toxicity (Anneken et al., 2015).

Simmler et al. (2013) reported blood brain barrier permeability at nearly identical in vitro rates as METH for both MEPH and MeCa, but METH is reported to have 5 times the brain-to-plasma ratio in vivo compared to MEPH (Martinez-Clemente et al., 2013, Melega et al., 1995), so it is possible that in vivo, decreased drug availability due to the polarity of the β-keto substitution could account for the required higher doses and lessened toxicity. Alternatively,
MEPH has lessened potency at the DAT compared to METH, due to the presence of the β-keto group negatively impacting the binding affinity of these compounds for the neurotransmitter transporters, and thus requiring higher doses to elicit transmitter release (Simmler et al., 2013). As this excessive DA release is thought to contribute to the toxicity of METH by increasing the amount of oxidative stress and free radicals through DA metabolism, promoting persistent inflammatory activation and eventual synaptic damage (Thomas et al., 2008), it was important to investigate the other DA-dependent behavioral and physiological effects of these drugs, such as body temperature and locomotor activity.

As shown in Fig. 3, a dose-dependent increase in core body temperature was observed with 4MM, and was significant for all doses tested. This effect peaked at 1.5-2°C, which is similar to but lower in magnitude than METH (Anneken et al., 2015). In animals given MeCa, there were also dose-dependent changes to core body temperature, but the pattern differed from either 4MM or METH. In the lower dose groups, there was a significant increase in core temperature peaking at 1.5-2.0°C. However, at 80 mg/kg, there was marked hypothermia following each drug injection, dropping to 3-4°C below control levels, and slowly recovering to baseline. MEPH, when administered to mice at 20 or 40 mg/kg as a binge regimen, causes a similar immediate 2-3°C reduction in body temperature (Angoa-Perez et al., 2012). However, unlike MeCa, this recovers quickly and the overall effect of MEPH is to elicit significant hyperthermia. It has been demonstrated by Shortall et al. (2015) that the initial hypothermia elicited by MEPH is due to serotonergic signaling through 5-HT₁ receptors, as both preemptive 5-HT depletion and blockade of 5-HT₁ receptors attenuated hypothermia. Thus it is possible that MeCa at 80 mg/kg interacts with the serotonergic system in a manner not possible at lower drug concentrations. In support of this hypothesis, Simmler et al. (2013) reported that MeCa has a
relatively lower affinity for the 5-HT transporter that could account for such a difference at higher dosage.

Hyperlocomotion and increased stereotypy are both hallmarks of stimulant drugs, including METH. Horizontal hyperlocomotion is primarily mediated by the increase in DA signaling elicited by METH treatment, as mice lacking in DAT expression or treated with pharmacological agents interfering with the ability of METH to release DA have been shown to attenuate the acute motor stimulant effect of the drug (Fukushima et al., 2007, Kaushal et al., 2011, Matsumoto et al., 2008, Yoo et al., 2008). Interestingly, it has been demonstrated by Glickstein and Schmauss (2004) that an intermediate dose of METH (5 mg/kg) in mice initially elicited an increase in horizontal locomotor activity, but after multiple injections in a binge regimen, mice exhibited predominantly stereotyped behavior, a change not observed in mice that lacked D₂ DA receptors. Supporting the differential roles of D₁ and D₂ receptors, Kelly et al. (2008) reported a diminished but still significant increase in horizontal locomotor activity in D₂ receptor deficient mice, indicating a primary role for these receptors in mediating stereotypy but only a contributory role in hyperlocomotion. This is in agreement with other studies that implicate D₂ receptor activation in stereotypy by abolishing the behaviors through pharmacological reduction of DA release (Kitanaka et al., 2015, Mori et al., 2004, Tatsuta et al., 2006).

As MEPH has also been shown by multiple groups to promote both hyperlocomotion and stereotypy (Angoa-Perez et al., 2012, Baumann et al., 2012, Kehr et al., 2011), the intermediate compounds used in the present study were expected to elicit the same type of behaviors. In Fig. 4, MeCa only significantly increased horizontal movement time at the lowest dose tested, while it greatly increased stereotypy at all doses. On the other hand, 4MM significantly increased
horizontal activity at several doses, and while there a trend toward increased stereotyped behavior, this only achieved significance at 5 mg/kg and 40 mg/kg, and was lesser in magnitude than the increases seen in MeCa. If, in fact, predominance of stereotypy over hyperlocomotion reflects greater DA release and preferential D$_2$ receptor activation, then it would be reasonable to conclude that MeCa releases DA in greater amounts compared to 4MM since it elicits less horizontal and more stereotyped activity. In support of this conclusion, although there are no studies on 4MM release, an in vitro study found the magnitude of DA release mediated by MeCa to be similar to METH, and greater than that of MEPH (Simmler et al., 2013). Consequently, a greater release in DA would promote the hypothesis that MeCa would induce greater neurotoxicity than MEPH and/or 4MM, since it has been shown in multiple studies that increasing the amount of DA available for release enhances METH toxicity (Kita et al., 1995, Thomas et al., 2008, 2009). Indeed, the depletion levels reported above support this hypothesis.

The most unusual aspect of the observed MeCa toxicity is lesser toxicity at 80 mg/kg when compared to 40 mg/kg. The most likely reason for this effect is the marked hypothermia observed at this dosage. Reductions in core body temperature have long been known to be protective against METH neurotoxicity (Ali et al., 1994, Ali et al., 1996). The drastic drop in body temperature elicited by MeCa may provide a slight level of neuroprotection in a similar manner at this higher dose.

The temperature and drug availability factors that may impact MeCa toxicity are not as relevant for 4MM, which almost completely lacks the toxicity of METH or even MeCa. It still elicits hyperthermia, and should readily cross the blood brain barrier like METH, as it lacks the polar β-keto group. As its toxic profile is most similar to MEPH, it seems that the substitution on
the phenyl ring is more crucial to MEPH’s lack of direct toxic potential than the β-keto substitution seen in MeCa.

It has been demonstrated by Eshleman et al. (2013) that MEPH lacks binding affinity for VMAT₂ compared to METH. METH binds this transporter in much the same way it does DAT, inhibiting and reversing its function, releasing vesicular DA into the cytoplasm where it can subsequently be released via DAT. Whereas METH can release both cytosolic and vesicular stores, MEPH is only able to access the newly synthesized DA in the cytosol, limiting the amount of neurotransmitter it can release. Increasing the available pool of DA by either VMAT₂ inhibition or exogenous supplementation is known to potentiate the toxicity of METH (Thomas et al., 2008, 2009). Thus, it is feasible that the inability of MEPH to release DA via VMAT₂ would blunt its neurotoxic potential. If this were the case, it would indicate that the crucial determining mechanism leading to lasting neurotoxicity is the release of a threshold amount of DA. It is tempting to speculate that the methyl substituent in MEPH and 4MM reduces its binding affinity for VMAT₂, and thus its ability to release sufficient DA to initiate the neurotoxic cascade. The contribution of reduced DA availability and release to the observed lack of direct toxicity in these compounds is the focus of ongoing investigation in this laboratory. Should this prove fruitful, then therapeutic intervention for METH toxicity could target a specific, initiating event in the process, and potentially reduce the health care burden associated with METH abuse.
Acknowledgements

We would like to thank Dr. Roxanne Vaughn for her generous gift of DAT antibodies. We would also to thank the NIDA Drug Supply Program for providing methamphetamine and methcathinone for these and prior studies. The authors declare no conflicts of interest. All experiments were performed in compliance with ARRIVE guidelines.

Authorship Contributions

Participated in research design: Anneken, Angoa-Perez, and Kuhn.

Conducted experiments: Anneken.

Contributed new reagents or analytic tools: Sati and Crich.

Performed data analysis: Anneken.

Wrote or contributed to the writing or editing of the manuscript: Anneken, Angoa-Perez, Sati, Crich, and Kuhn.
References


Motbey CP, Clemens KJ, Apetz N, Winstock AR, Ramsey J, Li KM, Wyatt N, Callaghan PD,
Bowen MT, Cornish JL, McGregor IS (2013) High levels of intravenous mephedrone (4-
methylmethcathinone) self-administration in rats: Neural consequences and comparison

Motbey CP, Karanges E, Li KM, Wilkinson S, Winstock AR, Ramsay J, Hicks C, Kendig MD,

Shortall SE, Spicer CH, Ebling FJ, Green AR, Fone KC, King MV (2016) Contribution of
serotonin and dopamine to changes in core body temperature and locomotor activity in

Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC,

(1996) Neurotoxic and pharmacologic studies on enantiomers of the n-methylated analog
of cathinone (methcathinone): A new drug of abuse. *J Pharmacol Exp Ther* **279**:1043-
1052.


dopamine determines the severity of methamphetamine-induced neurotoxicity. *J
Neurochem* **105**:605-616.


Footnotes

This work was supported by the National Institute on Drug Abuse [Grant DA 039667]
Figure Legends

**Fig. 1.** Comparative structures of METH, 4MM, MeCa, and MEPH. This figure demonstrates the structural differences between neurotoxic METH, non-neurotoxic MEPH, and their intermediates.

**Fig. 2.** Effects of 4MM and MeCa on markers of dopaminergic toxicity. Mice were treated with 4MM (4 x 2.5, 5, 10, 20, or 40 mg/kg), MeCa (4 x 10, 20, 40, or 80 mg/kg) or saline vehicle every 2 h for a total of 4 injections at the given dose. Levels of DA (A), DAT (B), TH (C), and GFAP (D) were determined 48 h after drug exposure. Data are means ± SEM (for 4MM: control: n = 18; 2.5 mg/kg: n = 8; 5 mg/kg: n = 8; 10 mg/kg: n = 9; 20 mg/kg: n = 12; 40 mg/kg: n = 12; for MeCa: control: n = 15; 10 mg/kg: n = 6; 20 mg/kg: n = 6; 40 mg/kg: n = 11; 80 mg/kg: n = 10). Each experiment was performed 3 times, with differing doses, and results were then pooled for analysis. METH and MEPH data were reprinted for comparison from Anneken et al. (2015) with permission from John Wiley and Sons, Inc. These data are not statistically analyzed in the present figure, but METH elicited highly significant toxic effects on each measure in the original experiments, while MEPH had no significant effects. One-way ANOVA, * p < 0.05 ** p < 0.01 *** p < 0.001 **** p < 0.0001 compared to controls, with Bonferroni’s post hoc Test.

**Fig. 3.** Effects of 4MM and MeCa on core body temperature. Mice were treated with A) 4MM (4 x 2.5, 5, 10, 20 or 40 mg/kg), C) MeCa (4 x 20, 40, or 80 mg/kg) or saline vehicle every 2 h for a total of 4 injections. Body temperature was monitored beginning 40 min prior to the first injection via telemetry, and was measured at 20 min intervals for the duration of the experiment. Data are mean temperature values with SEMs (<5% of the mean for each group) omitted for clarity (4MM: control: n = 4; 2.5-20 mg/kg: n = 4; 40 mg/kg: n = 5; for MeCa: control: n = 9; 20
mg/kg: n = 6; 40 mg/kg: n = 10; 80 mg/kg: n = 8). This experiment was performed once for
4MM, and repeated twice with differing doses for MeCa. The mean difference from control
animals over the course of the entire experiment for each dose is shown in B and D ± SEMs.
Two-way repeated measures ANOVA, **** p < 0.0001 compared to controls, with Bonferroni’s
post hoc Test.

Fig. 4. Effects of 4MM and MeCa on locomotor behavior. Mice were treated with 4MM (4 x 2.5,
5, 10, 20, or 40 mg/kg), MeCa (4 x 20, 40, or 80 mg/kg), or saline vehicle every 2 h for a total of
4 injections. Horizontal activity (A), movement time (B), and stereotypy time (C) were
monitored for 60 min following each injection. Data are mean values ± SEMs (4MM: control: n
= 10; 2.5 mg/kg: n = 4; 5-40 mg/kg: n = 5; for MeCa: all groups: n = 4). This experiment was
performed twice for 4MM and once for MeCa with differing doses, though due to equipment size
constraints, each experiment was performed over consecutive days. One-way ANOVA, * p <
0.05 ** p < 0.01 *** p < 0.001 **** p < 0.0001 compared to controls, with Bonferroni’s post
hoc Test.
Figure 1

[Diagram showing chemical structures and reactions involving MEPH, 4MM, MeCa, and METH]
Figure 2

A

B

C

D

This article has not been copyedited and formatted. The final version may differ from this version.
Figure 3

A

B

C

D

Mean Δ vs Control (°C)

Mean Δ vs Control (°C)

Time (minutes)

Temperature (°C)

Time (minutes)

Temperature (°C)

Dose (mg/kg)

Control

4MM 2.5

4MM 5

4MM 10

4MM 20

4MM 40

Control

MeCa 20

MeCa 40

MeCa 80
Figure 4

A. Horizontal Beam Breaks (x 10^4)

- Control
- 4MM
- MeCa

B. Movement Time (s)

C. Stereotypy Time (s)

Dose (mg/kg)